Warner Chilcott cuts 500 jobs across Europe to off-set Actonel exclusivity loss
This article was originally published in Scrip
Executive Summary
Warner Chilcott has reported plans to restructure its Western European operations in markets where it lost exclusivity for its osteoporosis drug, Actonel (risedronate) late last year – a move that could lead to the loss of around 500 jobs.